SUMMARY Investigation by cerebral biopsy of patients with dementia associated with cerebral atrophy permits the examination of clinico-pathochemical relationships, and provides a means of distinguishing and classifying forms of cerebral atrophy. Benefits of the procedure must however be weighed against possible adverse effects of surgical intervention. The study examines Al-zheimer's disease in order to include them in therapeutic trials using oral choline and a parenteral cholinergic agonist.
The diagnosis and classification of cerebral atrophy in the presenium is imprecise, since clinical differentiation depends upon accurate neuropsychological characterisation and neuropathological and biochemical correlation. Necropsy investigations inevitably are of terminal pathological change and complete neurochemical analysis is prejudiced by post-mortem tissue autolysis. Moreover, patients in the advanced stage of disease may not be psychologically testable, and thus clinical distinctions between patients may not be evident.
Investigations of patients with presenile dementia in relatively early stages of disease by use of cerebral biopsy"2 have been informative. Nevertheless, there is reluctance to resort to invasive procedures if an effective treatment is lacking. Recent findings of neurochemical deficits in patients with Alzheimer's disease have however opened up the possibility of symptomatic treatment, increasing the need for accurate definition of patient groups. Clinical studies without pathochemical verification may be misleading.
Benefits arising from accurate diagnosis must however be weighed against potential risks of biopsy. Objection to the procedure would be justified if accelerated deterioration followed surgical intervention. This paper presents information regarding the outcome of 24 patients who have undergone cerebral biopsy for investigations of primary degenerative dementia in the presenium. The investigations were designed to differentiate forms of cerebral atrophy and their pathogenesis by examining the relationship between neuropsychological, pathological and biochemical data, and to identify patients with Alzheimer's disease in order to include them in therapeutic trials using oral choline and a parenteral cholinergic agonist.
Methods

Selection ofpatients
The 24 patients, previously described3 represent a subsection of patients investigated with a clinical diagnosis of primary cerebral atrophy. They were relatively youthful and otherwise physically well, and their relatives were educated, supportive and highly motivated to seek diagnosis and possible treatment. The progressive nature of the patient's condition was explained to relatives, and the use of biopsy as a means of defining the precise nature of the disease. Relatives were informed of potential surgical risks and that the intent of the investigations was directed toward greater understanding and possible treatment, and that the procedure was diagnostic and not itself therapeutic. It was emphasised that any resulting therapeutic trials would have no guarantee of success and would likely to be symptomatic rather than curative. Cerebral biopsy was carried out at the request and with the written consent of close relatives, only after the issues had been discussed at length with family and friends.
Neary, Snowden, Bowen, Sims, Mann, Yates, Davison Six-monthly review of patients currently being carried out includes assessment of orientation, object naming, verbal fluency, object recognition, block constructions, immediate and reversed digit span and immediate and delayed memory for name and address. These items were selected from the full clinical mental examination3 since (a) they sample the spectrum of disability found in the patient group, (b) they are sensitive to change, while avoiding floor and ceiling level performance in the patient population, (c) The length of survival in Alzheimer's disease is often regarded as 7 years, although reports suggest that a wide variation exists, ranging from 1 to 20 years.6
Long-term follow up of biopsied patients provides no evidence that the procedure has significantly altered their life expectancy. One patient died with a total length of history of only 3 years. Yet, his course had been rapid prior to biopsy, and there was no suggestion that the rate of decline had increased following the procedure. Most other patients are alive several years following biopsy, and many have surpassed their "predicted" 7 year life expectancy.
In conclusion, examination of a series of 24 patients, who have undergone cerebral biopsy for investigation of their dementia, has revealed no convincing evidence for permanent or accelerated adverse effects post-operatively apart from in one patient. The findings support the view that cerebral biopsy is a relatively safe procedure, provided rigorous standards are applied, ensuring the minimum time under general anaesthesia, the obtaining of minimal tissue possible for analysis, by a single senior neurosurgeon, who is aware of the tissue requirement but is nevertheless the sole arbiter of the minimal scale of dissection.
The results of clinical, pathological and chemical data obtained from this group of patients have indicated that cerebral atrophy is a heterogeneous group of disorders of which Alzheimer's disease is the most common. However, the clinical presentation of Alzheimer's disease in the presenium is not uniform, and patients without Alzheimer's disease may share clinical characteristics similar to those of Alzheimer's disease.3 Correlative studies in Alzheimer's disease have permitted comment on the relative contributions of cortical and subcortical disorders in the dementia of Alzheimer's disease.7 The availability of tissue from cerebral biopsy permits the possibility of examining many major neurotransmitters including glutamic acid.8 Patients with proven Alzheimer's disease have entered therapeutic trials of orally administered choline and a parenterally administered cholinergic agonist.
